GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nabriva Therapeutics PLC (OTCPK:NBRVF) » Definitions » Cash, Cash Equivalents, Marketable Securities

Nabriva Therapeutics (Nabriva Therapeutics) Cash, Cash Equivalents, Marketable Securities : $2.18 Mil (As of Jun. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Nabriva Therapeutics Cash, Cash Equivalents, Marketable Securities?

Nabriva Therapeutics's quarterly cash, cash equivalents, marketable securities declined from Dec. 2022 ($12.41 Mil) to Mar. 2023 ($1.80 Mil) but then increased from Mar. 2023 ($1.80 Mil) to Jun. 2023 ($2.18 Mil).

Nabriva Therapeutics's annual cash, cash equivalents, marketable securities increased from Dec. 2020 ($41.38 Mil) to Dec. 2021 ($47.68 Mil) but then declined from Dec. 2021 ($47.68 Mil) to Dec. 2022 ($12.41 Mil).


Nabriva Therapeutics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Nabriva Therapeutics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nabriva Therapeutics Cash, Cash Equivalents, Marketable Securities Chart

Nabriva Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 102.23 86.19 41.38 47.68 12.41

Nabriva Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.04 14.65 12.41 1.80 2.18

Nabriva Therapeutics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Nabriva Therapeutics  (OTCPK:NBRVF) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Nabriva Therapeutics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Nabriva Therapeutics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Nabriva Therapeutics (Nabriva Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nabriva Therapeutics PLC (OTCPK:NBRVF) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
N/A
Address
Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
Executives
Hogan H Michael Iii officer: Chief Executive Officer C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
David Maggio officer: Chief Financial Officer 15950 N. DALLAS PARKWAY, SUITE 600, DALLAS TX 75248
Mark Corrigan director
Broom Colin Md officer: Chief Executive Officer 119 FRINGETREE DRIVE, WEST CHESTER PA 19380
Stephen W Webster director C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Daniel D Burgess director C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Carrie L. Bourdow officer: Director C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Rowland Charles A Jr director 3338 LANCASHIRE RD, FURLONG PA 18925
Theodore R Schroeder officer: Chief Executive Officer 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
J. Christopher Naftzger officer: General Counsel and Corp Sec 633 LOWTHER ROAD, LEWISBERRY PA 17339
Christine J. Guico-pabia officer: Chief Medical Officer C/O NABRIVA THERAPEUTICS PLC, 414 COMMERCE DRIVE, SUITE 120, FORT WASHINGTON PA 19034
Lisa Dalton director 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Daniel Dolan officer: Chief Financial Officer C/O NABRIVA THERAPEUTICS PLC, 1000 CONTINENTAL DRIVE, SUITE 600, KING OF PRUSSIA PA 19406
Francesco Maria Lavino officer: Chief Commercial Officer 1000 CONTINENTAL DRIVE, SUITE 600, KING OF PRUSSIA PA 19406
Robert Crotty officer: General Counsel & Corp Sec. 1301 2ND AVE, SEATTLE WA 98101

Nabriva Therapeutics (Nabriva Therapeutics) Headlines

From GuruFocus